Home » Newsletters » BioWorld Science

BioWorld Science

March 31, 2008

View Archived Issues

Remedial agents for renal disorders disclosed in recent NovaCardia patent

Recent Leo patent describes new therapeutic options for hyperparathyroidism

Novel therapeutic agents for cancer reported in recent patent literature

IGFI receptor mutations implicated in human longevity

Levodopa effective when added to behavioral therapy for cocaine dependence

Advanced Cancer Therapeutics signs exclusive license for the University of Louisville's 4-IPP

Metabolon signs agreement for diagnostic test for the accurate dosing of warfarin

Valproic acid derivative with HDAC inhibitory activity shows antitumor activity in vivo

NICE issues positive final appraisal determination of Acomplia for obesity

Metabolex begins phase I clinical trial of MBX-2982 for type 2 diabetes

FluoroPharma signs licensing agreement with MGH in AD diagnosis and treatment

Vivus completes enrollment in phase III EQUIP trial of Qnexa in obese patients

Shire enters copromotion agreement with TAP Pharmaceutical for Lialda in ulcerative colitis

SGX reports results from two phase I clinical trials of SGX-523 in cancer

Omrix initiates phase II clinical trial of fibrin patch in mild to moderate bleeding

NanoViricides to initiate animal trials of HIV therapeutic HivCide-I

Karo Bio initiates second phase IIb clinical study of eprotirome in dyslipidemia

SIGA reports positive results from phase I clinical trial of ST-246 for smallpox

FDA grants approval to Neurologix to initiate phase II clinical trial of gene transfer therapy

Phase II clinical trial results confirm competitive profile of Orexo's OX-17 in GERD

FDA approves Schering-Plough's label revisions for Pegintron and Rebetol in HCV

Mochida's novel CB2 agonist shows analgesic activity in rat inflammatory pain models

Sound raises funds for clinical studies to test oral hearing loss candidate SPI-1005

KY-201 shows better safety profile than rosiglitazone in preclinical studies

AnGes receives approval to manufacture and market Naglazyme for MPS VI

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 3, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...